Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Squamous Cell Carcinoma Age: Adult |
Dose: Intravenous, Intramuscular, or Subcutaneous – 0.25-0.5 unit/kg (10 to 20 unit/m²) Frequency: weekly or twice weekly |
|
Indication: Testicular Carcinoma Age: Adult |
Dose: Intravenous, Intramuscular, or Subcutaneous – 0.25-0.5 unit/kg (10 to 20 unit/m²) Frequency: weekly or twice weekly |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Not recommended Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment CrCl greater than 50 mL/min |
Dose: Dose: Note: Dose adjustment not necessary |
|
Condition: Renal Impairment CrCl 40-50 mL/min |
Dose: Dose: Note: 70% of normal dose |
Administration
- For hospital use only
- Must be diluted properly
Side Effect
- Mucocutaneous toxicity including rash
- erythema
- hyperpigmentation
- urticaria (More than 50%)
- Febrile reactions
- acute (25-50%)
- Mucositis (30%)
- Stomatitis (30%)
- Interstitial pneumonitis (10%)
- Pulmonary fibrosis (10%)
- Anorexia
- Weight loss
- Rales
- Tachypnea
- Alopecia (1-10%)
- Fatal pulmonary fibrosis (1%)
- Confusion
- Shivering
- Anphylactoid rxns
- Onycholysis
- Pruritus
- Skin thickening
- Skleroderma
- Nausea
- Malaise
- Myocardial infarction
- Hypotension
- Cerebral vascular accident
- Raynaud's phenomenon
- Fatal pulmonary fibrosis
- Hepatotoxicity
- Renal toxicity
- Necrolysis
- Hyperpigmentation
- Pulmonary toxicity
- interstitial pneumonitis
- fibrosis
- cardiorespiratory collapse in patients with lymphoma
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Previous or concurrent radiotherapy to the chest
|
Increased incidence and severity of lung toxicity
|
|
Vinca Alkaloids (Vincristine, Vinblastine, Vinorelbine)
|
May result in a syndrome corresponding to morbus Raynaud
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Pulmonary Disease
|
Risk of fatal lung toxicity
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store between 2-8°C. Protect from light and should not be used after the expiration date is reached.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.